Bowden C R, White K D, Lewis U J, Tutwiler G F
Metabolism. 1985 Mar;34(3):237-43. doi: 10.1016/0026-0495(85)90006-x.
To determine whether the rapid lipolytic effect observed with human growth hormone (hGH) preparations in rabbits and rabbit adipose tissue is an intrinsic property of the hormone, we examined the lipolytic effects in vivo and in vitro of clinical grade preparations, hGH purified by DEAE cellulose chromatography, and hGH prepared by recombinant DNA techniques. Using isolated rabbit perirenal adipocytes, ACTH and clinical-grade hGH preparations both stimulated glycerol release to the same maximal rate with half-maximal hGH effects observed between 8 and 50 micrograms/mL. Purification of the most potent lipolytic preparation of clinical grade hGH by DEAE cellulose chromatography yielded a preparation (2 IU/mg of growth activity that retained insulinlike effects on rat fat pad [U-14C] glucose metabolism) that, at concentrations up to 0.2 mg/mL, failed to stimulate lipolysis by adipocytes incubated for one or four hours in the presence or absence of dexamethasone or trypsin inhibitor or when preincubated for three hours prior to addition of hGH. Recombinant DNA-derived hGH did not stimulate glycerol release at 0.1 mg/mL. While antiserum to purified hGH blocked the increase in glucose oxidation in rat fat pads produced by clinical grade hGH, it did not inhibit its lipolytic effect using rabbit adipocytes. Purified hGH (0.1 mg/kg IV) was also unable to elicit a rise in serum free fatty acid (FFA) levels of conscious rabbits while, at the same dose, clinical grade hGH increased FFA levels to 900 microEq/L over basal. Rapid lipolytic stimulation in rabbit adipocytes by hGH preparations could not be attributed to the 20,000 molecular weight variant of hGH (hGH20K) or the peptide corresponding to positions 32 to 46 of hGH (deletion peptide).(ABSTRACT TRUNCATED AT 250 WORDS)
为了确定在兔子及兔脂肪组织中观察到的人生长激素(hGH)制剂的快速脂解作用是否为该激素的固有特性,我们检测了临床级制剂、经二乙氨基乙基纤维素色谱法纯化的hGH以及通过重组DNA技术制备的hGH在体内和体外的脂解作用。使用分离的兔肾周脂肪细胞,促肾上腺皮质激素(ACTH)和临床级hGH制剂均能以相同的最大速率刺激甘油释放,hGH的半数最大效应在8至50微克/毫升之间观察到。对临床级hGH最有效的脂解制剂进行二乙氨基乙基纤维素色谱法纯化,得到一种制剂(生长活性为2国际单位/毫克,对大鼠脂肪垫[U-14C]葡萄糖代谢保留胰岛素样作用),该制剂在浓度高达0.2毫克/毫升时,无论是否存在地塞米松或胰蛋白酶抑制剂,或在添加hGH前预先孵育3小时,均未能刺激脂肪细胞在孵育1小时或4小时后发生脂解。重组DNA来源的hGH在0.1毫克/毫升时未刺激甘油释放。虽然针对纯化hGH的抗血清可阻断临床级hGH引起的大鼠脂肪垫葡萄糖氧化增加,但使用兔脂肪细胞时并未抑制其脂解作用。纯化的hGH(0.1毫克/千克静脉注射)也无法使清醒兔子的血清游离脂肪酸(FFA)水平升高,而相同剂量下,临床级hGH可使FFA水平比基础值升高至900微当量/升。hGH制剂对兔脂肪细胞的快速脂解刺激作用不能归因于hGH的20,000分子量变体(hGH20K)或对应于hGH第32至46位的肽段(缺失肽段)。(摘要截短于250字)